| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | -0.085 | 0.008 |
| mRNA | avrainvillamide | CTRPv2 | pan-cancer | AAC | 0.11 | 0.008 |
| mRNA | NSC 74859 | CTRPv2 | pan-cancer | AAC | 0.098 | 0.01 |
| mRNA | Nutlin-3 | CTRPv2 | pan-cancer | AAC | 0.084 | 0.01 |
| mRNA | SMER-3 | CTRPv2 | pan-cancer | AAC | -0.092 | 0.01 |
| mRNA | ISOX:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.085 | 0.01 |
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | 0.071 | 0.02 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | -0.08 | 0.02 |
| mRNA | BRD-K51490254 | CTRPv2 | pan-cancer | AAC | 0.086 | 0.02 |
| mRNA | Compound 23 citrate | CTRPv2 | pan-cancer | AAC | 0.075 | 0.03 |